Skip to main content
SpringerLink
Log in

Genetics of Uveal Melanoma

  • Chapter
  • First Online:
Intraocular Tumors

Abstract

Uveal melanoma is a rare, aggressive intraocular malignant tumor, leading to metastatic disease in over 50% of patients with tumors located in the ciliary body or choroid. Genetic studies have identified chromosomal changes, mutations and gene expression profiles linked to both tumour development and progression. In this chapter we present the current knowledge surrounding these key molecular changes, how they are being used to predict metastatic risk, their functional relevance to tumor biology and how they may inform the identification of therapeutic targets to treat metastatic disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Damato BE, Coupland SE. Differences in uveal melanomas between men and women from the British Isles. Eye (Lond). 2012;26(2):292–9.

    CAS  Google Scholar 

  2. Khan S, Finger PT, Yu GP, Razzaq L, Jager MJ, de Keizer RJ, et al. Clinical and pathologic characteristics of biopsy-proven iris melanoma: a multicenter international study. Arch Ophthalmol. 2012;130(1):57–64.

    PubMed  Google Scholar 

  3. Krishna Y, Kalirai H, Thornton S, Damato BE, Heimann H, Coupland SE. Genetic findings in treatment-naive and proton-beam-radiated iris melanomas. Br J Ophthalmol. 2016;100(7):1012–6.

    PubMed  Google Scholar 

  4. Caines R, Eleuteri A, Kalirai H, Fisher AC, Heimann H, Damato BE, et al. Cluster analysis of multiplex ligation-dependent probe amplification data in choroidal melanoma. Mol Vis. 2015;21:1–11.

    CAS  PubMed  PubMed Central  Google Scholar 

  5. Coupland SE, Lake SL, Zeschnigk M, Damato BE. Molecular pathology of uveal melanoma. Eye (Lond). 2013;27(2):230–42.

    CAS  Google Scholar 

  6. Harbour JW. A prognostic test to predict the risk of metastasis in uveal melanoma based on a 15-gene expression profile. Methods Mol Biol. 2014;1102:427–40.

    CAS  PubMed  PubMed Central  Google Scholar 

  7. Carvajal RD. Update on the treatment of uveal melanoma. Clin Adv Hematol Oncol. 2016;14(10):768–70.

    PubMed  Google Scholar 

  8. Carvajal RD, Schwartz GK, Tezel T, Marr B, Francis JH, Nathan PD. Metastatic disease from uveal melanoma: treatment options and future prospects. Br J Ophthalmol. 2017;101(1):38–44.

    PubMed  Google Scholar 

  9. Woodman SE. Metastatic uveal melanoma: biology and emerging treatments. Cancer J. 2012;18(2):148–52.

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Carvajal RD, Yavuzyigitoglu S, Drabarek W, Smit KN, van Poppelen N, Koopmans AE, et al. Update on the treatment of uveal melanoma. Clin Adv Hematol Oncol. 2016;14(10):768–70.

    PubMed  Google Scholar 

  11. Damato B, Dopierala JA, Coupland SE. Genotypic profiling of 452 choroidal melanomas with multiplex ligation-dependent probe amplification. Clin Cancer Res. 2010;16(24):6083–92.

    CAS  PubMed  Google Scholar 

  12. Ehlers JP, Worley L, Onken MD, Harbour JW. Integrative genomic analysis of aneuploidy in uveal melanoma. Clin Cancer Res. 2008;14(1):115–22.

    CAS  PubMed  Google Scholar 

  13. Robertson AG, Shih J, Yau C, Gibb EA, Oba J, Mungall KL, et al. Integrative analysis identifies four molecular and clinical subsets in uveal melanoma. Cancer Cell. 2017;32(2):204–20.e15.

    CAS  PubMed  PubMed Central  Google Scholar 

  14. de Lange MJ, van Pelt SI, Versluis M, Jordanova ES, Kroes WG, Ruivenkamp C, et al. Heterogeneity revealed by integrated genomic analysis uncovers a molecular switch in malignant uveal melanoma. Oncotarget. 2015;6(35):37824–35.

    PubMed  PubMed Central  Google Scholar 

  15. Ehlers JP, Harbour JW. Molecular pathobiology of uveal melanoma. Int Ophthalmol Clin. 2006;46(1):167–80.

    PubMed  Google Scholar 

  16. Kilic E, van Gils W, Lodder E, Beverloo HB, van Til ME, Mooy CM, et al. Clinical and cytogenetic analyses in uveal melanoma. Invest Ophthalmol Vis Sci. 2006;47(9):3703–7.

    PubMed  Google Scholar 

  17. Singh N, Singh AD, Hide W. Inferring an evolutionary tree of uveal melanoma from genomic copy number aberrations. Invest Ophthalmol Vis Sci. 2015;56(11):6801–9.

    CAS  PubMed  Google Scholar 

  18. Damato B, Eleuteri A, Taktak AF, Coupland SE. Estimating prognosis for survival after treatment of choroidal melanoma. Prog Retin Eye Res. 2011;30(5):285–95.

    PubMed  Google Scholar 

  19. Dogrusoz M, Bagger M, van Duinen SG, Kroes WG, Ruivenkamp CA, Bohringer S, et al. The prognostic value of AJCC staging in uveal melanoma is enhanced by adding chromosome 3 and 8q status. Invest Ophthalmol Vis Sci. 2017;58(2):833–42.

    PubMed  Google Scholar 

  20. Eleuteri A, Damato B, Coupland SE, Taktak A. Enhancing survival prognostication in patients with choroidal melanoma by integrating pathologic, clinical and genetic predictors of metastasis. Int J Biomed Eng Technol. 2012;8(1):18–35.

    Google Scholar 

  21. DeParis SW, Taktak A, Eleuteri A, Enanoria W, Heimann H, Coupland SE, et al. External validation of the liverpool uveal melanoma prognosticator online. Invest Ophthalmol Vis Sci. 2016;57(14):6116–22.

    PubMed  Google Scholar 

  22. Vaquero-Garcia J, Lalonde E, Ewens KG, Ebrahimzadeh J, Richard-Yutz J, Shields CL, et al. PRiMeUM: a model for predicting risk of metastasis in uveal melanoma. Invest Ophthalmol Vis Sci. 2017;58(10):4096–105.

    PubMed  PubMed Central  Google Scholar 

  23. Coupland SE, Damato BE. Molecular analysis of uveal melanoma. Ophthalmology. 2013;120(7):e50.

    PubMed  Google Scholar 

  24. Tschentscher F, Prescher G, Zeschnigk M, Horsthemke B, Lohmann DR. Identification of chromosomes 3, 6, and 8 aberrations in uveal melanoma by microsatellite analysis in comparison to comparative genomic hybridization. Cancer Genet Cytogenet. 2000;122(1):13–7.

    CAS  PubMed  Google Scholar 

  25. Hussain RN, Kalirai H, Groenewald C, Kacperek A, Errington RD, Coupland SE, et al. Prognostic biopsy of choroidal melanoma after proton beam radiation therapy. Ophthalmology. 2016;123(10):2264–5.

    PubMed  Google Scholar 

  26. Onken MD, Worley LA, Ehlers JP, Harbour JW. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res. 2004;64(20):7205–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Tschentscher F, Husing J, Holter T, Kruse E, Dresen IG, Jockel KH, et al. Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct entities. Cancer Res. 2003;63(10):2578–84.

    CAS  PubMed  Google Scholar 

  28. Zuidervaart W, van der Velden PA, Hurks MH, van Nieuwpoort FA, Out-Luiting CJ, Singh AD, et al. Gene expression profiling identifies tumour markers potentially playing a role in uveal melanoma development. Br J Cancer. 2003;89(10):1914–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  29. Chang SH, Worley LA, Onken MD, Harbour JW. Prognostic biomarkers in uveal melanoma: evidence for a stem cell-like phenotype associated with metastasis. Melanoma Res. 2008;18(3):191–200.

    CAS  PubMed  Google Scholar 

  30. Field MG, Harbour JW. Recent developments in prognostic and predictive testing in uveal melanoma. Curr Opin Ophthalmol. 2014;25(3):234–9.

    PubMed  PubMed Central  Google Scholar 

  31. Field MG, Durante MA, Decatur CL, Tarlan B, Oelschlager KM, Stone JF, et al. Epigenetic reprogramming and aberrant expression of PRAME are associated with increased metastatic risk in Class 1 and Class 2 uveal melanomas. Oncotarget. 2016;7(37):59209–19.

    PubMed  PubMed Central  Google Scholar 

  32. Onken MD, Worley LA, Char DH, Augsburger JJ, Correa ZM, Nudleman E, et al. Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophthalmology. 2012;119(8):1596–603.

    PubMed  Google Scholar 

  33. Decatur CL, Ong E, Garg N, Anbunathan H, Bowcock AM, Field MG, et al. Driver mutations in uveal melanoma: associations with gene expression profile and patient outcomes. JAMA Ophthalmol. 2016;134(7):728–33.

    PubMed  PubMed Central  Google Scholar 

  34. Dono M, Angelini G, Cecconi M, Amaro A, Esposito AI, Mirisola V, et al. Mutation frequencies of GNAQ, GNA11, BAP1, SF3B1, EIF1AX and TERT in uveal melanoma: detection of an activating mutation in the TERT gene promoter in a single case of uveal melanoma. Br J Cancer. 2014;110(4):1058–65.

    CAS  PubMed  PubMed Central  Google Scholar 

  35. Harbour JW, Onken MD, Roberson ED, Duan S, Cao L, Worley LA, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science. 2010;330(6009):1410–3.

    CAS  PubMed  PubMed Central  Google Scholar 

  36. Harbour JW, Roberson ED, Anbunathan H, Onken MD, Worley LA, Bowcock AM. Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma. Nat Genet. 2013;45(2):133–5.

    CAS  PubMed  PubMed Central  Google Scholar 

  37. Martin M, Masshofer L, Temming P, Rahmann S, Metz C, Bornfeld N, et al. Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3. Nat Genet. 2013;45(8):933–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  38. Royer-Bertrand B, Torsello M, Rimoldi D, El Zaoui I, Cisarova K, Pescini-Gobert R, et al. Comprehensive genetic landscape of uveal melanoma by whole-genome sequencing. Am J Hum Genet. 2016;99(5):1190–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  39. Van Raamsdonk CD, Bezrookove V, Green G, Bauer J, Gaugler L, O’Brien JM, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature. 2009;457(7229):599–602.

    PubMed  Google Scholar 

  40. Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S, Wiesner T, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med. 2010;363(23):2191–9.

    PubMed  PubMed Central  Google Scholar 

  41. Yavuzyigitoglu S, Drabarek W, Smit KN, van Poppelen N, Koopmans AE, Vaarwater J, et al. Correlation of gene mutation status with copy number profile in uveal melanoma. Ophthalmology. 2017;124(4):573–5.

    PubMed  Google Scholar 

  42. Yavuzyigitoglu S, Koopmans AE, Verdijk RM, Vaarwater J, Eussen B, van Bodegom A, et al. Uveal melanomas with SF3B1 mutations: a distinct subclass associated with late-onset metastases. Ophthalmology. 2016;123(5):1118–28.

    PubMed  Google Scholar 

  43. Onken MD, Worley LA, Long MD, Duan S, Council ML, Bowcock AM, et al. Oncogenic mutations in GNAQ occur early in uveal melanoma. Invest Ophthalmol Vis Sci. 2008;49(12):5230–4.

    PubMed  Google Scholar 

  44. Scholz SL, Moller I, Reis H, Susskind D, van de Nes JAP, Leonardelli S, et al. Frequent GNAQ, GNA11, and EIF1AX mutations in iris melanoma. Invest Ophthalmol Vis Sci. 2017;58(9):3464–70.

    CAS  PubMed  Google Scholar 

  45. Mudhar HS, Doherty R, Salawu A, Sisley K, Rennie IG. Immunohistochemical and molecular pathology of ocular uveal melanocytoma: evidence for somatic GNAQ mutations. Br J Ophthalmol. 2013;97(7):924–8.

    PubMed  Google Scholar 

  46. Vader MJC, Madigan MC, Versluis M, Suleiman HM, Gezgin G, Gruis NA, et al. GNAQ and GNA11 mutations and downstream YAP activation in choroidal nevi. Br J Cancer. 2017;117(6):884–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  47. Metz CH, Scheulen M, Bornfeld N, Lohmann D, Zeschnigk M. Ultradeep sequencing detects GNAQ and GNA11 mutations in cell-free DNA from plasma of patients with uveal melanoma. Cancer Med. 2013;2(2):208–15.

    CAS  PubMed  PubMed Central  Google Scholar 

  48. Shoushtari AN, Carvajal RD. GNAQ and GNA11 mutations in uveal melanoma. Melanoma Res. 2014;24(6):525–34.

    CAS  PubMed  Google Scholar 

  49. Chen X, Wu Q, Depeille P, Chen P, Thornton S, Kalirai H, et al. RasGRP3 mediates MAPK pathway activation in GNAQ mutant uveal melanoma. Cancer Cell. 2017;31(5):685–96.e6.

    CAS  PubMed  PubMed Central  Google Scholar 

  50. Ambrosini G, Pratilas CA, Qin LX, Tadi M, Surriga O, Carvajal RD, et al. Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance. Clin Cancer Res. 2012;18(13):3552–61.

    CAS  PubMed  PubMed Central  Google Scholar 

  51. Amirouchene-Angelozzi N, Frisch-Dit-Leitz E, Carita G, Dahmani A, Raymondie C, Liot G, et al. The mTOR inhibitor Everolimus synergizes with the PI3K inhibitor GDC0941 to enhance anti-tumor efficacy in uveal melanoma. Oncotarget. 2016;7(17):23633–46.

    PubMed  PubMed Central  Google Scholar 

  52. Chen X, Wu Q, Tan L, Porter D, Jager MJ, Emery C, et al. Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations. Oncogene. 2014;33(39):4724–34.

    CAS  PubMed  Google Scholar 

  53. Ho AL, Musi E, Ambrosini G, Nair JS, Deraje Vasudeva S, de Stanchina E, et al. Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype. PLoS One. 2012;7(7):e40439.

    CAS  PubMed  PubMed Central  Google Scholar 

  54. Khalili JS, Yu X, Wang J, Hayes BC, Davies MA, Lizee G, et al. Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner. Clin Cancer Res. 2012;18(16):4345–55.

    CAS  PubMed  PubMed Central  Google Scholar 

  55. Musi E, Ambrosini G, de Stanchina E, Schwartz GK. The phosphoinositide 3-kinase alpha selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ/GNA11-mutant uveal melanoma cells. Mol Cancer Ther. 2014;13(5):1044–53.

    CAS  PubMed  PubMed Central  Google Scholar 

  56. Komatsubara KM, Manson DK, Carvajal RD. Selumetinib for the treatment of metastatic uveal melanoma: past and future perspectives. Future Oncol. 2016;12(11):1331–44.

    CAS  PubMed  Google Scholar 

  57. Luke JJ, Triozzi PL, McKenna KC, Van Meir EG, Gershenwald JE, Bastian BC, et al. Biology of advanced uveal melanoma and next steps for clinical therapeutics. Pigment Cell Melanoma Res. 2015;28(2):135–47.

    PubMed  Google Scholar 

  58. Feng X, Degese MS, Iglesias-Bartolome R, Vaque JP, Molinolo AA, Rodrigues M, et al. Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. Cancer Cell. 2014;25(6):831–45.

    CAS  PubMed  PubMed Central  Google Scholar 

  59. Yu FX, Luo J, Mo JS, Liu G, Kim YC, Meng Z, et al. Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP. Cancer Cell. 2014;25(6):822–30.

    CAS  PubMed  PubMed Central  Google Scholar 

  60. Yoo JH, Shi DS, Grossmann AH, Sorensen LK, Tong Z, Mleynek TM, et al. ARF6 is an actionable node that orchestrates oncogenic GNAQ signaling in uveal melanoma. Cancer Cell. 2016;29(6):889–904.

    CAS  PubMed  PubMed Central  Google Scholar 

  61. Ewens KG, Kanetsky PA, Richards-Yutz J, Purrazzella J, Shields CL, Ganguly T, et al. Chromosome 3 status combined with BAP1 and EIF1AX mutation profiles are associated with metastasis in uveal melanoma. Invest Ophthalmol Vis Sci. 2014;55(8):5160–7.

    CAS  PubMed  Google Scholar 

  62. van Essen TH, van Pelt SI, Versluis M, Bronkhorst IH, van Duinen SG, Marinkovic M, et al. Prognostic parameters in uveal melanoma and their association with BAP1 expression. Br J Ophthalmol. 2014;98(12):1738–43.

    PubMed  Google Scholar 

  63. Yavuzyigitoglu S, Mensink HW, Smit KN, Vaarwater J, Verdijk RM, Beverloo B, et al. Metastatic disease in polyploid uveal melanoma patients is associated with BAP1 mutations. Invest Ophthalmol Vis Sci. 2016;57(4):2232–9.

    CAS  PubMed  Google Scholar 

  64. Jensen DE, Rauscher FJ 3rd. BAP1, a candidate tumor suppressor protein that interacts with BRCA1. Ann N Y Acad Sci. 1999;886:191–4.

    CAS  PubMed  Google Scholar 

  65. Carbone M, Yang H, Pass HI, Krausz T, Testa JR, Gaudino G. BAP1 and cancer. Nat Rev Cancer. 2013;13(3):153–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  66. Matatall KA, Agapova OA, Onken MD, Worley LA, Bowcock AM, Harbour JW. BAP1 deficiency causes loss of melanocytic cell identity in uveal melanoma. BMC Cancer. 2013;13:371.

    PubMed  PubMed Central  Google Scholar 

  67. Koopmans AE, Verdijk RM, Brouwer RW, van den Bosch TP, van den Berg MM, Vaarwater J, et al. Clinical significance of immunohistochemistry for detection of BAP1 mutations in uveal melanoma. Mod Pathol. 2014;27(10):1321–30.

    CAS  PubMed  Google Scholar 

  68. Kalirai H, Dodson A, Faqir S, Damato BE, Coupland SE. Lack of BAP1 protein expression in uveal melanoma is associated with increased metastatic risk and has utility in routine prognostic testing. Br J Cancer. 2014;111(7):1373–80.

    CAS  PubMed  PubMed Central  Google Scholar 

  69. Shah AA, Bourne TD, Murali R. BAP1 protein loss by immunohistochemistry: a potentially useful tool for prognostic prediction in patients with uveal melanoma. Pathology. 2013;45(7):651–6.

    CAS  PubMed  Google Scholar 

  70. Szalai E, Wells JR, Ward L, Grossniklaus HE. Uveal melanoma nuclear BRCA1-associated protein-1 immunoreactivity is an indicator of metastasis. Ophthalmology. 2018;125(2):203–9. https://doi.org/10.1016/j.ophtha.2017.07.018.

    Article  PubMed  Google Scholar 

  71. Griewank KG, van de Nes J, Schilling B, Moll I, Sucker A, Kakavand H, et al. Genetic and clinico-pathologic analysis of metastatic uveal melanoma. Mod Pathol. 2014;27(2):175–83.

    CAS  PubMed  Google Scholar 

  72. McCarthy C, Kalirai H, Lake SL, Dodson A, Damato BE, Coupland SE. Insights into genetic alterations of liver metastases from uveal melanoma. Pigment Cell Melanoma Res. 2016;29(1):60–7.

    CAS  PubMed  Google Scholar 

  73. Farquhar N, Thornton S, Coupland S, Coulson J, Sacco J, Krishna Y, et al. Patterns of BAP1 protein expression provide insights into prognostic significance and the biology of uveal melanoma. J Pathol Clin Res. 2017;4(1):26–38.

    PubMed  PubMed Central  Google Scholar 

  74. Landreville S, Agapova OA, Matatall KA, Kneass ZT, Onken MD, Lee RS, et al. Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma. Clin Cancer Res. 2012;18(2):408–16.

    CAS  PubMed  Google Scholar 

  75. Abdel-Rahman MH, Pilarski R, Cebulla CM, Massengill JB, Christopher BN, Boru G, et al. Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J Med Genet. 2011;48(12):856–9.

    CAS  PubMed  Google Scholar 

  76. Haugh AM, Njauw CN, Bubley JA, Verzi AE, Zhang B, Kudalkar E, et al. Genotypic and phenotypic features of BAP1 cancer syndrome: a report of 8 new families and review of cases in the literature. JAMA Dermatol. 2017;153(10):999–1006.

    PubMed  PubMed Central  Google Scholar 

  77. Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet. 2011;43(10):1022–5.

    CAS  PubMed  PubMed Central  Google Scholar 

  78. Rai K, Pilarski R, Boru G, Rehman M, Saqr AH, Massengill JB, et al. Germline BAP1 alterations in familial uveal melanoma. Genes Chromosomes Cancer. 2017;56(2):168–74.

    CAS  PubMed  Google Scholar 

  79. Pilarski R, Cebulla CM, Massengill JB, Rai K, Rich T, Strong L, et al. Expanding the clinical phenotype of hereditary BAP1 cancer predisposition syndrome, reporting three new cases. Genes Chromosomes Cancer. 2014;53(2):177–82.

    CAS  PubMed  Google Scholar 

  80. Rai K, Pilarski R, Cebulla CM, Abdel-Rahman MH. Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases. Clin Genet. 2016;89(3):285–94.

    CAS  PubMed  Google Scholar 

  81. Alsafadi S, Houy A, Battistella A, Popova T, Wassef M, Henry E, et al. Cancer-associated SF3B1 mutations affect alternative splicing by promoting alternative branchpoint usage. Nat Commun. 2016;7:10615.

    CAS  PubMed  PubMed Central  Google Scholar 

  82. Furney SJ, Pedersen M, Gentien D, Dumont AG, Rapinat A, Desjardins L, et al. SF3B1 mutations are associated with alternative splicing in uveal melanoma. Cancer Discov. 2013;3(10):1122–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  83. Johnson CP, Kim IK, Esmaeli B, Amin-Mansour A, Treacy DJ, Carter SL, et al. Systematic genomic and translational efficiency studies of uveal melanoma. PLoS One. 2017;12(6):e0178189.

    PubMed  PubMed Central  Google Scholar 

  84. Johansson P, Aoude LG, Wadt K, Glasson WJ, Warrier SK, Hewitt AW, et al. Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4. Oncotarget. 2016;7(4):4624–31.

    PubMed  Google Scholar 

  85. Moore AR, Ceraudo E, Sher JJ, Guan Y, Shoushtari AN, Chang MT, et al. Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma. Nat Genet. 2016;48(6):675–80.

    CAS  PubMed  PubMed Central  Google Scholar 

  86. Ehlers JP, Worley L, Onken MD, Harbour JW. DDEF1 is located in an amplified region of chromosome 8q and is overexpressed in uveal melanoma. Clin Cancer Res. 2005;11(10):3609–13.

    CAS  PubMed  Google Scholar 

  87. Laurent C, Valet F, Planque N, Silveri L, Maacha S, Anezo O, et al. High PTP4A3 phosphatase expression correlates with metastatic risk in uveal melanoma patients. Cancer Res. 2011;71(3):666–74.

    CAS  PubMed  Google Scholar 

  88. Worley LA, Long MD, Onken MD, Harbour JW. Micro-RNAs associated with metastasis in uveal melanoma identified by multiplexed microarray profiling. Melanoma Res. 2008;18(3):184–90.

    CAS  PubMed  Google Scholar 

  89. Radhakrishnan A, Badhrinarayanan N, Biswas J, Krishnakumar S. Analysis of chromosomal aberration (1, 3, and 8) and association of microRNAs in uveal melanoma. Mol Vis. 2009;15:2146–54.

    CAS  PubMed  PubMed Central  Google Scholar 

  90. Ling JW, Lu PR, Zhang YB, Jiang S, Zhang ZC. miR-367 promotes uveal melanoma cell proliferation and migration by regulating PTEN. Genet Mol Res. 2017;16:3. https://doi.org/10.4238/gmr16039067.

    Article  Google Scholar 

  91. Venkatesan N, Kanwar J, Deepa PR, Khetan V, Crowley TM, Raguraman R, et al. Clinico-pathological association of delineated miRNAs in uveal melanoma with monosomy 3/disomy 3 chromosomal aberrations. PLoS One. 2016;11(1):e0146128.

    PubMed  PubMed Central  Google Scholar 

  92. Zhou J, Jiang J, Wang S, Xia X. Oncogenic role of microRNA20a in human uveal melanoma. Mol Med Rep. 2016;14(2):1560–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  93. Yan D, Zhou X, Chen X, Hu DN, Dong XD, Wang J, et al. MicroRNA-34a inhibits uveal melanoma cell proliferation and migration through downregulation of c-Met. Invest Ophthalmol Vis Sci. 2009;50(4):1559–65.

    PubMed  Google Scholar 

  94. Chen X, Wang J, Shen H, Lu J, Li C, Hu DN, et al. Epigenetics, microRNAs, and carcinogenesis: functional role of microRNA-137 in uveal melanoma. Invest Ophthalmol Vis Sci. 2011;52(3):1193–9.

    CAS  PubMed  Google Scholar 

  95. Ma YB, Song DW, Nie RH, Mu GY, Yoo JH, Shi DS, et al. MicroRNA-32 functions as a tumor suppressor and directly targets EZH2 in uveal melanoma. Genet Mol Res. 2016;15(2):889–904.

    Google Scholar 

  96. Lu L, Yu X, Zhang L, Ding X, Pan H, Wen X, et al. The long non-coding RNA RHPN1-AS1 promotes uveal melanoma progression. Int J Mol Sci. 2017;18(1):pii: E226. https://doi.org/10.3390/ijms18010226.

    Article  CAS  Google Scholar 

  97. Maat W, van der Velden PA, Out-Luiting C, Plug M, Dirks-Mulder A, Jager MJ, et al. Epigenetic inactivation of RASSF1a in uveal melanoma. Invest Ophthalmol Vis Sci. 2007;48(2):486–90.

    PubMed  Google Scholar 

  98. Mobuchon L, Battistella A, Bardel C, Scelo G, Renoud A, Houy A, et al. A GWAS in uveal melanoma identifies risk polymorphisms in the CLPTM1L locus. NPJ Genom Med. 2017;2:pii: 5. https://doi.org/10.1038/s41525-017-0008-5.

    Article  CAS  Google Scholar 

  99. Krishna Y, McCarthy C, Kalirai H, Coupland SE. Inflammatory cell infiltrates in advanced metastatic uveal melanoma. Hum Pathol. 2017;66:159–66.

    CAS  PubMed  Google Scholar 

  100. Singh AD, Tubbs R, Biscotti C, Schoenfield L, Trizzoi P. Chromosomal 3 and 8 status within hepatic metastasis of uveal melanoma. Arch Pathol Lab Med. 2009;133(8):1223–7.

    PubMed  Google Scholar 

  101. Trolet J, Hupe P, Huon I, Lebigot I, Decraene C, Delattre O, et al. Genomic profiling and identification of high-risk uveal melanoma by array CGH analysis of primary tumors and liver metastases. Invest Ophthalmol Vis Sci. 2009;50(6):2572–80.

    PubMed  Google Scholar 

  102. Luscan A, Just PA, Briand A, Burin des Roziers C, Goussard P, Nitschke P, et al. Uveal melanoma hepatic metastases mutation spectrum analysis using targeted next-generation sequencing of 400 cancer genes. Br J Ophthalmol. 2015;99(4):437–9.

    CAS  PubMed  Google Scholar 

  103. Meir T, Dror R, Yu X, Qian J, Simon I, Pe’er J, et al. Molecular characteristics of liver metastases from uveal melanoma. Invest Ophthalmol Vis Sci. 2007;48(11):4890–6.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, UK

    Helen Kalirai & Sophie Thornton

  2. Department of Ocular Oncology and Radiology, Moscow Helmholtz Research Institute of Eye Diseases, Moscow, Russian Federation

    Alexander Iu. Tsygankov & Svetlana V. Saakyan

  3. Department of Eye Diseases, Moscow Helmholtz Research Institute of Eye Diseases, Moscow, Russian Federation

    Svetlana V. Saakyan

  4. Molecular and Clinical Cancer Medicine, Royal Liverpool and Broadgreen University, Hospital NHS Trust, University of Liverpool, Liverpool, UK

    Sarah E. Coupland

Authors
  1. Helen Kalirai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alexander Iu. Tsygankov
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sophie Thornton
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Svetlana V. Saakyan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sarah E. Coupland
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sarah E. Coupland .

Editor information

Editors and Affiliations

  1. Sankara Nethralaya, Chennai, Tamil Nadu, India

    Vikas Khetan

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Kalirai, H., Tsygankov, A.I., Thornton, S., Saakyan, S.V., Coupland, S.E. (2020). Genetics of Uveal Melanoma. In: Khetan, V. (eds) Intraocular Tumors. Springer, Singapore. https://doi.org/10.1007/978-981-15-0395-5_7

Download citation

  • DOI: https://doi.org/10.1007/978-981-15-0395-5_7

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-15-0394-8

  • Online ISBN: 978-981-15-0395-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation